Thyroid papillary carcinoma associated to Hashimoto's thyroiditis  by Campos, Luiz Alexandre Albuquerque Freixo et al.
77
Brazilian Journal of otorhinolaryngology 78 (6) novemBer/DecemBer 2012
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Thyroid papillary carcinoma associated to Hashimoto’s thyroiditis
Abstract
Luiz Alexandre Albuquerque Freixo Campos1, Sílvia Miguéis Picado2, André Vicente Guimarães3, 
Daniel Araki Ribeiro4, Rogério Aparecido Dedivitis5
There is controversy in the literature regarding the association between papillary thyroid carcinoma 
(PTC) and Hashimoto’s thyroiditis (HT) and as to what would be the etiological relationship between 
them.
Objective: To establish the proportion of cases among patients with TH and CPT, correlating it with 
histomorphological aspects.
Method: A retrospective study of patients undergoing partial or total thyroidectomy for PTC between 
2007 and 2009, a total of 41 cases.
Results: Regarding the association of HT and CPT, we found 11 cases (26.8%), all females, but 
without statistical significance. The mean age was 44.9 years among the patients with coexistent TH 
and CPT, whereas it was 49.1 years without that association. The average size of tumors in those 
without TH was 20.53 mm and for those with TH it was 12.72 mm (p = 0.4). Regarding pathology 
staging, the ratiosbetween those with and those without TH were kept in T1a, T1b and T3. In T2, 
there were no cases of coexistence of HT and PTC.
Conclusion: There is a rate of 26.8% of patients with association between TH and CPT, but without 
differences in relation to tumor size.
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INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most 
prevalent and the one with the best prognosis among all 
malignant thyroid neoplasias1,2. Hashimoto’s thyroiditis 
(HT) is a chronic lymphocytic thyroiditis, and the most 
common cause of hypothyroidism in areas with proper 
amounts of iodine3. In 1955, Dailey et al.4 proposed, for 
the first time, the association between PTC and HT, also 
suggested by numerous other authors5-11.
However, there are authors who disagree from such 
association12-14 in studies which were not clear as to the 
association, after following up patients with HT. One of 
the bases for discussion is the etiology, and it is not clear 
whether thyroiditis predisposes to cancer or if it is later 
induced by the neoplasia5.
There are studies which show the expression of 
RET/PTC-1 and RET/PTC-3 oncogenes in patients with 
HT, confirmed by phenotyping15,16, which could prove HT 
as a pre-neoplastic lesion. There was also a study which 
showed the concurrent p63 expression, a p53-homologous 
protein which regulate squamous cells in HT-suggestive 
cells without concurrent neoplasia and in typical PTC 
cells; present in high rates (around 80%) in these two 
groups and without significant expression in other thyroid 
involvements17.
Our paper aims at studying the possible significant 
association between these two entities and whether or 
not there are differences in the PTC presentation in pa-
tients with HT and those without. The goal is to find the 
incidence of HT cases in patients with PTC, correlating 
histomorphometric aspects.
METHOD
The present study was approved by the Ethics in 
Research Committee of the institution where it was carried 
out, under protocol # 013/2011.
We carried out a retrospective study based on data 
collected from the files of the hospital where the study 
was carried out, as well as from the charts of patients sub-
mitted to total or partial thyroidectomies, because of PTC 
in histopathology specimens, between the years of 2007 
and 2009, making up a total of 41 cases. We consecutively 
selected all the PTC cases, regardless of age or gender, 
with or without HT. We also investigated the incidence of 
Hashimoto’s thyroiditis in the remaining cases submitted 
to partial or total thyroidectomies for other reasons. We 
took off the study those patients with incomplete data in 
their charts.
The study was based on data collected from the 
patients’ charts, such as age, gender, tumor size and pa-
thology staging after surgery.
The statistical analysis was carried out after pre-
paring the data base. We then analyzed all the variables, 
investigating the statistical significance among the data, 
using the Fisher’s exact test.
RESULTS
In the time frame between 2007 and 2009, there 
were 315 thyroidectomies, 41 due to thyroid papillary 
carcinoma and 274 for other reasons. Of these 274 proce-
dures, 45 were partial thyroidectomies because of nodular 
goiter and, in none of them the pathologist found chronic 
thyroiditis. Among the cases submitted to total thyroidec-
tomy (n = 229), chronic thyroiditis was seen in 12.25%; 
if we consider only those patients operated because of 
atoxic multinodular goiter in this group, the incidence of 
thyroiditis drops down to 6.65% (Table 1).
Table 1. Thyroiditis in patients submitted to total thyroidectomy 
in the same period, taking off the cases of papillary carcinoma.
Thyroiditis present Without thyroiditis
Toxic diffuse goiter 9 0
Hashimoto’s thyroiditis 3 0
Other cancers 0 6
Atoxic multinodular goiter 13 198
Total 25 204
Thus, there were 41 total or partial thyroidecto-
mies due to papillary carcinoma of the thyroid. Of these, 
11 had concurrent HT (26.8%), while 30 did not have it 
(72.1%) - Table 2.
Table 2. Ratios between genders and the coexistence of PTC 
and HT.
PTC without HT (n/%) PTC with HT (n/%) total
Males 7 100 0 0 7
Females 23 67.6 11 32.5 34
Total 30 11 41
Thus, we found 11 cases of HT in 41 patients with 
papillary carcinoma (26.8%) and 13 cases of HT in 198 pa-
tients with multinodular goiter (6.65%), with statistical sig-
nificance considering the Fisher’s Exact Test (p = 0.005823).
Considering the demographic data from the 41 
patients, 34 (82.93%) were females, while seven (17.07%) 
were males.
Concerning the HT-PTC association, there were 11 
cases, all females, but without statistical significance. The 
mean age of the PTC cases was 48 years. In those cases 
of PTC concurrent with HT, the mean age was 44.9 years 
and without the association this value was 49.1 years. The 
minimum age among the patients was 20 years and the 
maximum was 91.
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The mean tumor size among those without thyroid-
itis was 20.53 mm and for those with thyroiditis it was 12.72 
mm, nevertheless, without statistical significance - p = 0.4.
As to the pathology staging, the ratios between 
those with HT and those who did not have it were main-
tained in T1a, T1b and T3. In T2, there were no cases of 
coexistence between HT and PTC (Table 3).
chronic thyroiditis15,20. The presence of RET/PTC must 
not be synonymous with cancer, but rather a molecular 
mechanisms of carcinogenesis21.
Another mechanism described is the p63 expres-
sion, a tumor-suppression protein homologous to the p53, 
which is found in about 81% of the HT and PTC, and it 
is not found in normal thyroid tissues, Graves disease or 
other thyroid tumors17.
In the present study, 26.8% of the cases showed 
both HT and PTC, which may suggest a correlation, even 
without control groups for a proper statistical analysis; 
however, consistent with literature data, reporting that it 
may vary between 20% and 37.5%3,22,23.
The predominance of females in this study, in both 
groups of patients, namely those associated with HT and 
those without such association, is in agreement with the 
literature3,5,8,11, an epidemiology matching PTC. It is known 
that thyroid autoimmune diseases are more commonly 
expressed in women when compared to men, and such 
trend is even more obvious in the post-menopausal period. 
However, our study did not yield statistically significant 
differences as far as gender is concerned, which may 
have been caused by the low number of men among 
the patients. The same can be inferred in relation to the 
mean age of those involved, there were no differences 
between the two groups, which is in agreement with the 
literature, with higher prevalence in individuals around 
50 years of age1,2,4.
Among the different stages of the disease, there 
were no statistically significant differences between the 
presence and absence of concurrent HT, which is also in 
agreement with the literature24. Some authors suggest a less 
aggressive course of the disease when there is association 
between HT and PTC3,23, with tendency towards a smaller 
tumor size, less lymph node involvement and longer sur-
vival25. A population study did not find statistically signi-
ficant difference based on the presence of HT, despite a 
tendency towards a better survival in cases of concurrent 
diseases11. The metanalysis of three studies, involving 2,552 
patients, carried out in the same publication, suggested 
a better disease-free survival among patients with PTC 
associated with HT. similarly, the global survival was also 
higher in this group in four of five studies which analyzed 
this parameter. The precise reason for such difference is 
still unclear.
The ultimate confirmation of a causal association be-
tween HT and PTC would require a longitudinal prospective 
study of patients with HT. Right now, the best approach for 
patients with HT, especially those with the nodular variant 
of the disease, is a careful follow up, clinically as well as 
with cytopathological study of the nodules. The surgical ap-
proach should be the total thyroidectomy, since the cases of 
concurrent diseases are more frequently multicentric (93%) 
when compared to cases without the association (50%)26.
Table 3. Rates of HT cases among the PTC stages.
PTC without HT (n/%) PTC with HT (n/%) total
T1a 9 69.2 4 30.8 13
T1b 8 61.5 5 38.5 13
T2 4 100 0 - 4
T3 9 81.8 2 18.2 11
total 30 73.2 11 26.8 41
DISCUSSION
HT was first described in 191218 as an autoimmune 
disease, affecting 5% of the general population and involv-
ing the diffuse infiltration of the thyroid by lymphocytes, 
fibrosis and gland parenchyma atrophy.
Since 19554, there are questions concerning the 
association between HT and PTC, with studies corrobo-
rating and studies disproving such association. This as-
sociation has been reported by many authors, although 
showing different indices, probably due not only to 
different genetic factors and different environments, but 
also the numerous pathology definitions used in the many 
studies7.
A metanalysis showed that the HT incidence is 2.77 
higher in patients with PTC when compared to patients 
with benign thyroid diseases. In addition, in patients with 
thyroid carcinoma, the association of HT is 1.99 times 
higher among those with PTC than in patients with other 
pathological types of thyroid cancer11. Indirectly, these 
findings my suggest a predisposition of HT patients to the 
development of PTC. In our series we found 26.8% of HT in 
41 cases of papillary carcinoma and 6.65% in 198 patients 
with multinodular goiter (p = 0.005823). Notwithstanding, 
in the present series there were 45 patients submitted to 
less-than-total thyroidectomy because of nodular goiter, 
therefore a benign disease, and in none of them we found 
thyroiditis, which is explained by the fact that we carried 
out total thyroidectomy as a routine in cases of nodular 
disease associated with HT. Thus, these 45 cases could 
not be included in this statistical analysis.
Therefore, the RET/PTC, which is a RET rearrange-
ment, a gene which codes a tyrosine-kinase receptor, is 
described as one of the mechanisms responsible for the 
association of HT and PTC19. This oncogene was found in 
the large majority of tissues with HT and without detect-
able PTC, which may show a progression to cancer from 
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CONCLUSION
There is a rate of 26.8% of patients with the HT-
PTC association, however without statistical significance 
vis-à-vis tumor size. More studies are needed in order to 
assess the higher development of neoplasia in patients 
with HT and assess the possible factors which may trigger 
the carcinogenesis, thus contributing to prevention, early 
diagnosis and target treatment.
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